Cargando…

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial

OBJECTIVE: To evaluate the long‐term safety and efficacy of add‐on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open‐label extension (OLE) of the randomized, placebo‐controlled phase 3 trial GWPCARE6 (NCT02544763). Results of an interim (Februar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thiele, Elizabeth A., Bebin, E. Martina, Filloux, Francis, Kwan, Patrick, Loftus, Rachael, Sahebkar, Farhad, Sparagana, Steven, Wheless, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305454/ https://www.ncbi.nlm.nih.gov/pubmed/34957550 http://dx.doi.org/10.1111/epi.17150

Ejemplares similares

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program
por: Gaston, Tyler E., et al.
Publicado: (2023)

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma
por: Bissler, John J., et al.
Publicado: (2017)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex
por: Sánchez Fernández, Iván, et al.
Publicado: (2020)

Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial
por: Wheless, Margaret C., et al.
Publicado: (2019)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
por: Franz, David N., et al.
Publicado: (2016)

Seizure Localization in Patients with Multiple Tubers: Presurgical Evaluation in Tuberous Sclerosis
por: Song, Pamela, et al.
Publicado: (2012)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
por: Tayo, Bola, et al.
Publicado: (2019)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
por: Silvinato, Antônio, et al.
Publicado: (2022)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
por: Kwan, Patrick, et al.
Publicado: (2017)

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy
por: Wheless, James W., et al.
Publicado: (2019)

Clinical seizure semiology is subtle and identification of seizures by parents is unreliable in infants with tuberous sclerosis complex
por: Lynch, Matthew, et al.
Publicado: (2022)

Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures
por: Franz, David N., et al.
Publicado: (2018)

Multivariate data analysis identifies natural clusters of Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND)
por: de Vries, Petrus J., et al.
Publicado: (2021)

Dispensary Cannabidiol (CBD): Nothing to Worry About!
por: Elliott, Taylor, et al.
Publicado: (2023)

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex
por: Sparagana, Steven, et al.
Publicado: (2017)

Clinical Progress of Epilepsy in Children with Tuberous Sclerosis: Prognostic Factors for Seizure Outcome
por: Park, Soo Min, et al.
Publicado: (2011)

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options
por: Wang, Shelly, et al.
Publicado: (2014)

Tuberous sclerosis
por: George, Anisha, et al.
Publicado: (2015)

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis
por: Bissler, John J., et al.
Publicado: (2018)

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives
por: Overwater, Iris E, et al.
Publicado: (2019)

Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic
por: Moloney, Patrick B., et al.
Publicado: (2021)

Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study
por: van Andel, Dorinde M., et al.
Publicado: (2020)

Burden of renal angiomyolipomas associated with tuberous sclerosis complex: results of a patient and caregiver survey
por: Rentz, Anne M., et al.
Publicado: (2018)

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy
por: Davis, Brittney H., et al.
Publicado: (2021)

AUTISM IN TUBEROUS SCLEROSIS
por: Khanna, Rakesh, et al.
Publicado: (1991)

Tuberous sclerosis with rhabdomyoma
por: Ajay, V., et al.
Publicado: (2013)

Tuberous (or Tuberose) Sclerosis
por: Fowler, J. S., et al.
Publicado: (1910)

Tubers and Tumors Are CLIPped Together in Tuberous Sclerosis Complex
por: Dang, Louis
Publicado: (2022)

Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs
por: Garcia, Gabriel A., et al.
Publicado: (2022)

Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorder
por: Prohl, Anna K., et al.
Publicado: (2019)

Cannabidiol for functional seizures (psychogenic nonepileptic seizures/attacks) and other stress‐associated disorders
por: Asadi‐Pooya, Ali A.
Publicado: (2023)

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
por: Zhang, Bo, et al.
Publicado: (2013)

Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label Study
por: Juarez-Martinez, Erika L., et al.
Publicado: (2022)

All tubers are not created equal: Cerebellar tubers in a pediatric patient with tuberous sclerosis
por: Weerasinghe, Sanjeeva, et al.
Publicado: (2020)

Variants Within TSC2 Exons 25 and 31 Are Very Unlikely to Cause Clinically Diagnosable Tuberous Sclerosis
por: Ekong, Rosemary, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nahrbjbfp46t104iicmgqc6rjq